|Slideshows|March 16, 2022

Bipolar Disorder: Sorting Out Comorbidities

Because patients with bipolar disorder often have underlying comorbidities, a thorough diagnosis is imperative.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Rapid Cycling, Lithium, and the Landscape of Bipolar Disorder: A Conversation With David Dunner, MD

ByJoseph F. Goldberg, MD,David Dunner, MD, FACPsych

May 13th 2026

Treating Bipolar Disorder: Early Intervention and the Role of Lithium

ByJoseph F. Goldberg, MD,Robert M. Post, MD

March 16th 2026

FDA Approves Bysanti for Treatment of Bipolar 1 Disorder and Schizophrenia

ByJessica Walters

February 20th 2026

FDA Approves Uzedy Once-Monthly Extended Release Injectable Suspension for Bipolar I Disorder

ByLeah Kuntz

October 16th 2025

FDA Approves Risperidone Extended-Release Injectable Suspension

ByJessica Walters

September 9th 2025

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Bipolar Disorder: Sorting Out Comorbidities

Related Content

Rapid Cycling, Lithium, and the Landscape of Bipolar Disorder: A Conversation With David Dunner, MD

Treating Bipolar Disorder: Early Intervention and the Role of Lithium

FDA Approves Bysanti for Treatment of Bipolar 1 Disorder and Schizophrenia

FDA Approves Uzedy Once-Monthly Extended Release Injectable Suspension for Bipolar I Disorder

FDA Approves Risperidone Extended-Release Injectable Suspension

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Monoamines: A Full House

Dose Lithium Once a Day at Night: An Update

Artificial Intelligence in Psychopharmacology: Promise and Pitfalls, With Roy Perlis, MD

Consensus on Overcoming Barriers to Long-Acting Injectable Use in Schizophrenia

Understanding the Complexities of Suicide Risk: A Conversation With Jill Harkavy-Friedman, PhD, and Elizabeth Ballard, PhD